Repligen (NASDAQ:RGEN) Price Target Raised to $225.00
The Cerbat Gem
What a Rare Market Pattern Signals for Investors
Fool.com Headlines
Amneal Pharmaceuticals (AMRX) After Shelf Filing Has Its Undervalued Case Under Fresh Scrutiny
Simply Wall St
Elanco (ELAN) Stock Still Looks Cheap Despite Its 93% Run
Simply Wall St
Skyworks Solutions (SWKS) Nears Merger Review End While Dropping Dividend For $2 Billion Buybacks
Simply Wall St
Martin Marietta Materials (MLM) Faces Cost And Lhoist Deal Questions As Valuation Debate Builds
Simply Wall St
Ascendis Pharma (ASND) ReACHin Data Keeps The Bull Case Alive As Valuation Questions Linger
Simply Wall St
Why Did Gartner (IT) Move Today?
Simply Wall St


